Role of downregulation of galectin-9 in the tumorigenesis of gastric cancer

Yang,Jiaxing; Zhu,Lin; Cai,Yong; Suo,Jian; Jin,Jingji

doi:10.3892/ijo.2014.2494

Role of downregulation of galectin-9 in the tumorigenesis of gastric cancer

Authors:
- Jiaxing Yang
- Lin Zhu
- Yong Cai
- Jian Suo
- Jingji Jin
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, School of Life Sciences, Jilin University, Changchun, Jilin 130012, P.R. China
Published online on: June 11, 2014 https://doi.org/10.3892/ijo.2014.2494
Pages: 1313-1320

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Galectin-9 (Gal-9), a member of the β-galactoside-binding galectin family, plays a role in immune response, apoptosis, cell proliferation and cell death. Recent studies have shown that abnormal expression of Gal-9 is involved in certain primary cancers. The present study is the first investigation of the role of Gal-9 gene expression in clinically diagnosed primary gastric cancer tissues. Gal-9 mRNA expression was assessed in 44 clinically diagnosed frozen primary cancer tissue samples using quantitative PCR (qPCR). Analysis of the qPCR data revealed a significant reduction (>2-fold decreased) of Gal-9 gene expression in gastric cancer tissues in 77% (34/44) of patients. In patients with gastric cancer, although no statistically significant difference was found between adjacent (<2 cm away from the cancer tissue) and normal tissues (>5 cm away from the cancer tissue), a >2-fold reduction in Gal-9 expression was observed in the adjacent tissues of 34% of the patients. Compared to matched normal or adjacent tissues, the gene expression of Gal-9 was significantly decreased in tumor tissues (p<0.001). The correlation of Gal-9 expression and clinicopathological features in gastric cancer was analyzed according to the TNM classification system using AJCC stage grouping. In patients with gastric cancer, clinical staging, tumor pathological stage (pT stage), tumor cell differentiation, lymph node metastasis and survival rate were found to be associated with Gal-9 expression. However, no significant association was found between Gal-9 expression and distant metastasis (p>0.05). No significant difference was found between patients of different genders, levels of cell differentiation, distant metastasis status or different survival time of patients. Compared to normal tissues, >2-fold reduction of Tim-3 expression in gastric cancer tissues occurred in 59% of patients, but no correlation was found between Gal-9 and Tim-3 in gastric cancer. These results strongly suggest that Gal-9 is involved in tumorigenesis of gastric cancer.

View Figures

View References

1	Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Felzi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K, Leffler H, Liu FT, Lotan R, Mercurio AM, Monsigny M, Pillai S, Poirer F, Raz A, Rigby PW, Rini JM and Wang JL: Galectins: a family of animal β-galactoside-binding lectins. Cell. 76:597–598. 1994.
2	Leffler H, Carlsson S, Hedlund M, Qian Y and Poirier F: Introduction to galectins. Glycoconj J. 19:433–440. 2004. View Article : Google Scholar
3	Hirabayashi J and Kasai K: The family of metazoan metal-independent beta-galectoside-binding lectins: structure, function and molecular evolution. Glycobiology. 3:297–304. 1993. View Article : Google Scholar : PubMed/NCBI
4	Heusschen R, Griffioen AW and Thijssen VL: Galectin-9 in tumor biology: a jack of multiple trades. Biochim Biophys Acta. 1836:177–185. 2013.PubMed/NCBI
5	Türeci O, Schmitt H, Fadle N, Pfreundschuh M and Sahin U: Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin’s disease. J Biol Chem. 272:6416–6422. 1997.PubMed/NCBI
6	Oda Y, Herrmann J, Gitt MA, Turck CW, Burlingame AL, Barondes SH and Leffler H: Soluble lactose-binding lectin from rat intestine with two different carbohydrate-binding domains in the same peptide chain. J Biol Chem. 268:5929–5939. 1993.PubMed/NCBI
7	Hadari YR, Paz K, Dekel R, Mestrovic T, Accili D and Zick Y: Galectin-8. A new rat lectin, related to galectin-4. J Biol Chem. 27:3447–3453. 1995.PubMed/NCBI
8	Sato M, Nishi N, Shoji H, Seki M, Hashidate T, Hirabayashi J, Kasai Ki K, Hata Y, Suzuki S, Hirashima M and Nakamura T: Functional analysis of the carbohydrate recognition domains and a linker peptide of galectin-9 as to eosinophil chemoattractant activity. Glycobiology. 12:171–197. 2002. View Article : Google Scholar : PubMed/NCBI
9	Oh JH, Yang JO, Hahn Y, Kim MR, Byun SS, Jeon YJ, Kim JM, Song KS, Noh SM, Kim S, Yoo HS, Kim YS and Kim NS: Transcriptome analysis of human gastric cancer. Mamm Genome. 16:942–954. 2005. View Article : Google Scholar : PubMed/NCBI
10	Zhang F, Zheng M, Qu Y, Li J, Ji J, Feng B, Lu A, Li J, Wang M and Liu B: Different roles of galectin-9 isoforms in modulating E-selectin expression and adhesion function in LoVo colon carcinoma cells. Mol Biol Rep. 36:823–830. 2009. View Article : Google Scholar
11	Kageshita T, Kashio Y, Yamaguchi A, Seki M, Abedin MJ, Nishi N, Shoji H, Nakamura T, Ono T and Hirashima M: Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer. 99:809–816. 2002. View Article : Google Scholar : PubMed/NCBI
12	Lu LH, Nakagawa R, Kashio Y, Ito A, Shoji H, Nishi N, Hirashima M, Yamaguchi A and Nakamura T: Charaterization of galectin-9-induced death of Jurkat T cells. J Biochem. 141:157–172. 2007. View Article : Google Scholar : PubMed/NCBI
13	Kobayashi T, Kuroda J, Ashihara E, Oomizu S, Terui Y, Taniyama A, Adachi S, Takagi T, Yamamoto M, Sasaki N, Horiike S, Hatake K, Yamauchi A, Hirashima M and Taniwaki M: Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways. Leukemia. 24:843–850. 2010. View Article : Google Scholar : PubMed/NCBI
14	Kashio Y, Nakamura K, Abedin MJ, Seki M, Nishi N, Yoshida N, Nakamura T and Hirashima M: Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol. 170:3631–3636. 2003. View Article : Google Scholar : PubMed/NCBI
15	Irie A, Yamauchi A, Kontani K, Kihara M, Liu D, Shirato Y, Seki M, Nishi N, Nakamura T, Yokomise H and Hirashima M: Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res. 11:2962–2968. 2005. View Article : Google Scholar : PubMed/NCBI
16	Zhang ZY, Dong JH, Chen YW, Wang XQ, Li CH, Wang J, Wang GQ, Li HL and Wang XD: Galectin-9 acts as a prognostic factor with antimetastatic potential in hepatocellular carcinoma. Asian Pac J Cancer Prev. 13:2503–2509. 2012. View Article : Google Scholar : PubMed/NCBI
17	Liang M, Ueno M, Oomizu S, Arikawa T, Shinonaga R, Zhang S, Yamauchi A and Hirashima M: Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma. J Cancer Res Clin Oncol. 134:899–907. 2008. View Article : Google Scholar : PubMed/NCBI
18	Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th edition. Springer; Chicago, IL: 2010
19	Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB and Kuchroo V: The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 6:1245–1252. 2005. View Article : Google Scholar : PubMed/NCBI
20	Cooper DN and Barondes SH: God must love galectins; he made so many of them. Glycobiology. 9:979–984. 1999. View Article : Google Scholar : PubMed/NCBI
21	Vyakarnam A, Dagher SF, Wang JL and Patterson RJ: Evidence for a role for galectin-1 in pre-mRNA splicing. Mol Cell Biol. 17:4730–4737. 1997.PubMed/NCBI
22	Kuwabara I, Kuwabara Y, Yang RY, Schuler M, Green DR, Zuraw BL, Hsu DK and Liu FT: Galectin-7 (PIG1) exhibits pro-apoptotic function through JNK activation and mitochondrial cytochrome c release. J Biol Chem. 277:3487–3497. 2002. View Article : Google Scholar : PubMed/NCBI
23	Yang RY, Hsu DK, Yu L, Ni J and Liu FT: Cell cycle regulation by galectin-12, a new member of the galectin superfamily. J Biol Chem. 276:20252–20260. 2001. View Article : Google Scholar : PubMed/NCBI
24	Elola MT, Wolfenstein-Todel C, Troncoso MF, Vasta GR and Rabinovich GA: Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci. 64:1679–1700. 2007. View Article : Google Scholar : PubMed/NCBI
25	Jiang J, Jin MS, Kong F, Cao D, Ma HX, Jia Z, Wang YP, Suo J and Cao X: Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer. Plos One. 8:e817992013. View Article : Google Scholar : PubMed/NCBI
26	Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel RA, Freeman GJ and Kuchroo VK: Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 415:536–541. 2002. View Article : Google Scholar : PubMed/NCBI
27	Tang ZH, Liang S, Potter J, Jiang X, Mao HQ and Li Z: Tim-3/galectin-9 regulate the homeostasis of hepatic NKT cells in a murine model of nonalcoholic fatty liver disease. J Immunol. 190:1788–1796. 2013. View Article : Google Scholar : PubMed/NCBI